Solid tumor testing involves diagnostic and molecular testing conducted on solid tumors, which are abnormal cell masses or growths that form in various body tissues. This type of testing is employed to detect cancer cells or cancer-related DNA in the blood of patients with solid tumors, even if the cancer is not yet visible on imaging tests.
The main types of solid tumor testing include genetic testing and conventional testing. Genetic testing is a medical test that examines an individual's DNA (genetic material) to identify changes or variations in genes, chromosomes, or proteins. This testing is applied in the treatment of various cancer types, including breast cancer, lung cancer, colorectal cancer, prostate cancer, and cervical cancer. Solid tumor testing serves various applications, including clinical and research purposes, and is utilized by diverse end-users such as hospitals, pharmaceutical and biotechnology companies, contract research organizations, and academic research institutions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The solid tumor testing market research report is one of a series of new reports from The Business Research Company that provides solid tumor testing market statistics, including solid tumor testing industry global market size, regional shares, competitors with a solid tumor testing market share, detailed solid tumor testing market segments, market trends and opportunities, and any further data you may need to thrive in the solid tumor testing industry. This solid tumor testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The solid tumor testing market size has grown strongly in recent years. It will grow from $27.96 billion in 2024 to $29.94 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to personalized or precision medicine, poor tumor-selective drug delivery, low therapeutic efficacy, unsustainable costs, reductionist approaches to cancer chemotherapies.
The solid tumor testing market size is expected to see strong growth in the next few years. It will grow to $39.95 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing prevalence of cancer, increasing healthcare infrastructure, emergence of ai and iot-based diagnostic devices, increasing government initiatives. Major trends in the forecast period include advancements in diagnostic tools, introduction of nanocarrier-based therapies, strategic collaborations, strategic collaborations, next-generation testing device.
The forecast of 7.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of liquid biopsy panels and genomic sequencing kits for solid tumors sourced from Singapore and Sweden, thereby slowing diagnostic turnaround times and elevating pathology lab costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The solid tumor testing market is anticipated to experience growth, driven by an increase in the prevalence of cancer. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, often in the form of solid tumors, remains a significant health concern. Solid tumor testing plays a crucial role in detecting cancer cells, even before they are visible on imaging tests. As of June 2023, a report from the Centers for Disease Control and Prevention revealed 1,603,844 new cancer cases and 602,347 cancer-related deaths in the US in 2020. The escalating prevalence of cancer, with 403 new cases and 144 cancer-related deaths reported for every 100,000 people, is a key factor propelling the growth of the solid tumor testing market.
The increasing healthcare expenditure is significantly driving the growth of the solid tumor testing market. Healthcare expenditure encompasses all costs related to health services, family planning, nutrition activities, and emergency health aid, excluding expenses for drinking water and sanitation. The rise in healthcare spending and reimbursement support for cancer diagnostics is boosting the solid tumor testing market. By exploring innovative solutions and optimizing testing strategies, we can enhance cancer diagnosis effectiveness. For example, a report from the Office for National Statistics, a UK government department, revealed that between 2022 and 2023, healthcare spending in the UK grew by 5.6%, compared to a 0.9% increase in 2022. The UK's healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Thus, the growing healthcare expenditure is expected to propel the solid tumor testing market.
A key trend in the solid tumor testing market is the emergence of innovative liquid biopsy test solutions. Major players in the market are actively engaged in developing liquid biopsy tests to enhance their market positions. In June 2020, NeoGenomics Inc., a US-based testing laboratory company, introduced a suite of three solid tumor liquid biopsy tests designed to detect cancer cells in the blood of patients with solid tumors. These tests offer non-invasive, early detection, and FDA-approved solutions, aiding in personalized treatment decisions with a quick turnaround time of seven days or fewer.
Companies in the solid tumor testing market are also focused on developing liquid biopsy platforms. These platforms utilize various technologies to analyze body fluids, typically blood, for cancer-related biomarkers. For instance, in January 2023, PrognomiQ, a US-based healthcare company, launched a multi-omics liquid biopsy platform. The platform is part of an ongoing prospective clinical program aiming to enroll 15,000 subjects, with a focus on leveraging multi-omics markers to distinguish between cancer and controls.
In June 2023, Quest Diagnostics, a US-based medical laboratory company, acquired Haystack Oncology Inc for $450 million. This acquisition is aimed at expanding access to liquid biopsy technology, strengthening research and development capabilities, and increasing market share in cancer diagnostics. Haystack Oncology Inc., an early-stage oncology company, specializes in developing solid tumor testing technology to improve outcomes for patients with cancer.
Major companies operating in the solid tumor testing market include Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company (BD), Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Novocure Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Eutropics Pharmaceuticals Inc., Anixa Biosciences Inc., Cellular Biomedicine Group.
North America was the largest region in the solid tumor testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the solid tumor testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The solid tumor testing market consists of revenues earned by entities by providing molecular profiling, next-generation sequencing, immunohistochemistry, fluorescence in situ hybridization (FISH), and biomarker testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Solid Tumor Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on solid tumor testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for solid tumor testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The solid tumor testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Genetic Testing; Conventional Testing
- 2) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Cervical Cancer
- 3) By Application: Clinical; Research
- 4) By End-Users: Hospitals; Pharmaceutical And Biotechnology Companies; Contract Research Organizations; Academic Research Institutions
- Subsegments:
- 1) By Genetic Testing: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Fluorescence In Situ Hybridization (FISH)
- 2) By Conventional Testing: Histopathology; Cytology; Imaging Techniques
- Companies Mentioned: Johnson & Johnson Ltd; Roche Diagnostics Corporation; Thermo Fisher Scientific Inc.; Abbott Molecular Inc.; Becton Dickinson And Company (BD); Quest Diagnostics Incorporated; Tosoh Corporation; Agilent Technologies Inc.; bioMerieux Inc.; Beckman Coulter Inc.; Bio-Rad Laboratories Inc.; QIAGEN GmbH; Miltenyi Biotec GmbH; Natera Inc.; Myriad Genetics Inc.; Novocure Inc.; Invitae Corporation; Guardant Health Inc.; Foundation Medicine Inc.; Epic Sciences Inc.; Biocare Medical LLC; Agena Bioscience Inc.; Caris Life Sciences Inc.; 20/20 Gene Systems Inc.; Grail Inc.; Avant Diagnostics Inc.; Genomic Testing Cooperative; Eutropics Pharmaceuticals Inc.; Anixa Biosciences Inc.; Cellular Biomedicine Group.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Solid Tumor Testing Market Characteristics
3. Solid Tumor Testing Market Trends And Strategies
4. Solid Tumor Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Solid Tumor Testing Growth Analysis And Strategic Analysis Framework
- 5.1. Global Solid Tumor Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Solid Tumor Testing Market Growth Rate Analysis
- 5.4. Global Solid Tumor Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Solid Tumor Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Solid Tumor Testing Total Addressable Market (TAM)
6. Solid Tumor Testing Market Segmentation
- 6.1. Global Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Genetic Testing
- Conventional Testing
- 6.2. Global Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
- 6.3. Global Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Clinical
- Research
- 6.4. Global Solid Tumor Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Pharmaceutical And Biotechnology Companies
- Contract Research Organizations
- Academic Research Institutions
- 6.5. Global Solid Tumor Testing Market, Sub-Segmentation Of Genetic Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Fluorescence In Situ Hybridization (FISH)
- 6.6. Global Solid Tumor Testing Market, Sub-Segmentation Of Conventional Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Histopathology
- Cytology
- Imaging Techniques
7. Solid Tumor Testing Market Regional And Country Analysis
- 7.1. Global Solid Tumor Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Solid Tumor Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Solid Tumor Testing Market
- 8.1. Asia-Pacific Solid Tumor Testing Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Solid Tumor Testing Market
- 9.1. China Solid Tumor Testing Market Overview
- 9.2. China Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Solid Tumor Testing Market
- 10.1. India Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Solid Tumor Testing Market
- 11.1. Japan Solid Tumor Testing Market Overview
- 11.2. Japan Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Solid Tumor Testing Market
- 12.1. Australia Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Solid Tumor Testing Market
- 13.1. Indonesia Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Solid Tumor Testing Market
- 14.1. South Korea Solid Tumor Testing Market Overview
- 14.2. South Korea Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Solid Tumor Testing Market
- 15.1. Western Europe Solid Tumor Testing Market Overview
- 15.2. Western Europe Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Solid Tumor Testing Market
- 16.1. UK Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Solid Tumor Testing Market
- 17.1. Germany Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Solid Tumor Testing Market
- 18.1. France Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Solid Tumor Testing Market
- 19.1. Italy Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Solid Tumor Testing Market
- 20.1. Spain Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Solid Tumor Testing Market
- 21.1. Eastern Europe Solid Tumor Testing Market Overview
- 21.2. Eastern Europe Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Solid Tumor Testing Market
- 22.1. Russia Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Solid Tumor Testing Market
- 23.1. North America Solid Tumor Testing Market Overview
- 23.2. North America Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Solid Tumor Testing Market
- 24.1. USA Solid Tumor Testing Market Overview
- 24.2. USA Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Solid Tumor Testing Market
- 25.1. Canada Solid Tumor Testing Market Overview
- 25.2. Canada Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Solid Tumor Testing Market
- 26.1. South America Solid Tumor Testing Market Overview
- 26.2. South America Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Solid Tumor Testing Market
- 27.1. Brazil Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Solid Tumor Testing Market
- 28.1. Middle East Solid Tumor Testing Market Overview
- 28.2. Middle East Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Solid Tumor Testing Market
- 29.1. Africa Solid Tumor Testing Market Overview
- 29.2. Africa Solid Tumor Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Solid Tumor Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Solid Tumor Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Solid Tumor Testing Market Competitive Landscape And Company Profiles
- 30.1. Solid Tumor Testing Market Competitive Landscape
- 30.2. Solid Tumor Testing Market Company Profiles
- 30.2.1. Johnson & Johnson Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Diagnostics Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Abbott Molecular Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Becton Dickinson And Company (BD) Overview, Products and Services, Strategy and Financial Analysis
31. Solid Tumor Testing Market Other Major And Innovative Companies
- 31.1. Quest Diagnostics Incorporated
- 31.2. Tosoh Corporation
- 31.3. Agilent Technologies Inc.
- 31.4. bioMerieux Inc.
- 31.5. Beckman Coulter Inc.
- 31.6. Bio-Rad Laboratories Inc.
- 31.7. QIAGEN GmbH
- 31.8. Miltenyi Biotec GmbH
- 31.9. Natera Inc.
- 31.10. Myriad Genetics Inc.
- 31.11. Novocure Inc.
- 31.12. Invitae Corporation
- 31.13. Guardant Health Inc.
- 31.14. Foundation Medicine Inc.
- 31.15. Epic Sciences Inc.
32. Global Solid Tumor Testing Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Solid Tumor Testing Market
34. Recent Developments In The Solid Tumor Testing Market
35. Solid Tumor Testing Market High Potential Countries, Segments and Strategies
- 35.1 Solid Tumor Testing Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Solid Tumor Testing Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Solid Tumor Testing Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
